How shall we apply the new biology to diagnostics in surgical pathology?

Journal of Pathology

Volumn 187, Issue 1, 1999, Pages 147-154

  Jones, Dan ^a   Fletcher, Christopher D M ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Diagnosis; FISH; Immunohistochemistry; Molecular biology; Morphology; PCR

Indexed keywords

TUMOR MARKER;

CANCER DIAGNOSIS; CANCER THERAPY; CLINICAL PRACTICE; COST BENEFIT ANALYSIS; FLUORESCENCE IN SITU HYBRIDIZATION; IMMUNOHISTOCHEMISTRY; MOLECULAR GENETICS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REVIEW;

GENETIC TECHNIQUES; HUMANS; NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 0032954093     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9896(199901)187:1<147::AID-PATH230>3.0.CO;2-S     Document Type: Review

References (67)

1. Banks PM, Chan J, Cleary ML, et al. Mantle cell lymphoma: a proposal for unification of morphologic, immunologic and molecular data. Am J Surg Pathol 1992; 16: 637-642.
2. Isaacson P, Wright DH. Extranodal malignant lymphoma arising from mucosa-associated lymphoid tissue. Cancer 1984; 53: 2515-2524.
3. Gerald WL, Miller HK, Battifora H, Miettinen M, Silva EG, Rosai J. Intra-abdominal desmoplastic small round-cell tumour. Report of 19 cases of a distinctive type of high-grade polyphenotypic malignancy affecting young individuals. Am J Surg Pathol 1991; 15: 499-513.
4. Rubin B, Fletcher JA, Fletcher CDM. The histologic, genetic, and biological relationships between dermatofibrosarcoma protuberans and giant cell fibroblastoma: an unexpected story. Adv Anat Pathol 1997; 5: 336-341.
5. Shmookler BM, Enzinger FM, Weiss SW. Giant cell fibroblastoma: a juvenile form of dermatofibroscarcoma protuberans. Cancer 1989; 64: 2154-2161.
6. Bhattacharjee MB, Armstrong DD, Vogel H, Cooley LD. Cytogenetic analysis of 120 primary pediatric brain tumours and literature review. Cancer Genet Cytogenet 1997; 97: 39-53.
7. Versteege I, Sevenet N, Lange J, et al. Truncating mutations of hSNF5/INII in aggressive paediatric cancer. Nature 1998; 394: 203-206.
8. Loughran TP Jr. Clonal diseases of large granular lymphocytes. Blood 1993; 82: 1-14.
9. Ansell J, Bhagwan J, Cohen S, Sullivan J, Sherman D. Histiocytic lymphoma and malignant angioendotheliomatosis: one disease or two? Cancer 1982; 50: 1506-1512.
10. Wick MR, Mills SE, Scheithauer BW, Cooper PH, Davitz MA, Parkinson K. Reassessment of malignant 'angioendotheliomatosis' - evidence in favour of its reclassification as 'intravascular lymphomatosis'. Am J Surg Pathol 1986; 10: 112-123.
11. DiGiuseppe JA, Nelson WG, Seifter EJ, Boitnott JK, Mann RB. Intravascular lymphomatosis: a clinicopathologic study of 10 cases and assessment of response to chemotherapy. J Clin Oncol 1994; 12: 2573-2579.
12. Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumours. Science 1998; 279: 577-580.
13. Kindblom LG, Remotti HE, Aldenborg F, Meis-Kindblom JM. Gastrointestinal pacemaker cell tumour (GIPACT): gastrointestinal stromal tumours show phenotypic characteristics of the interstitial cells of Cajal. Am J Pathol 1998; 152: 1259-1269.
14. Benharroch D, Meguerian-Bedoyan Z, Lamant L, et al. ALK-positive lymphoma: a single disease with a broad spectrum of morphology. Blood 1998; 91: 2076-2084.
15. Folpe AL, Schmidt RA, Chapman D, Gown AM. Poorly differentiated synovial sarcoma. Immunohistochemical distinction from primitive neuroectodermal tumours and high-grade malignant peripheral nerve sheath tumours. Am J Surg Pathol 1998; 22: 673-682.
16. Lage JM, Sheikh SS. Genetic aspects of gestational trophoblastic diseases: a general overview with emphasis on new approaches in determining genetic composition. Gen Diagn Pathol 1997; 143: 109-115.
17. Lage JM, Driscoll SG, Yavner DL, Olivier AP, Mark SD, Weinberg DS. Hydatidiform moles. Application of flow cytometry in diagnosis. Am J Clin Pathol 1988; 89: 596-600.
18. Delattre O, Zucman J, Melot T, et al. The Ewing family of tumours a subgroup of small-round-cell tumours defined by specific chimeric transcripts. N Engl J Med 1994; 331: 294-299.
19. Busam KJ, Fletcher CDM. The clinical role of molecular genetics in soft tissue tumour pathology. Cancer Metastasis Rev 1997; 16: 207-227.
20. Zueman J, Delattre O, Desmaze C, et al. FWS and ATF-1 gene fusion induced by t(12;22) translocation in malignant melanoma of soft parts. Nature Genet 1993; 4: 341-345.
21. Labelle Y, Zucman J, Stemnan G, et al. Oncogene conversion of a novel orphan nuclear receptor by chromosome translocation. Hum Mol Genet 1995; 4: 2219-2226.
22. Ladanyi M, Gerald W. Fusion of the EWS and WT1 genes in the desmoplastic small round cell tumour. Cancer Res 1994; 54: 2837-2840.
23. Katz RL, Quezado M, Senderowicz AM, Villalba L, Laskin WB, Tsokos M. An intra-abdominal small round cell neoplasm with features of primitive neuroectodermal and desmoplastic round cell tumour and a EWS/FLI-1 fusion transcript. Hum Pathol 1997; 28: 502-509.
24. Kim J, Lee K, Pelletier J. The desmoplastic small round cell tumour t(11;22) translocation produces EWS/WTI isoforms with differing oncogenic properties. Oncogene 1998; 16: 1973-1979.
25. Granados R, Cibas ES, Fletcher JA. Cytogenetic analysis of effusions from malignant mesothelioma. A diagnostic adjunct to cytology. Acta Cytol 1994; 38: 711-717.
26. Smillie D. A PCR SSP method for detecting the Cys282Tyr mutation in the HFE gene associated with hereditary haemochromatosis. Mol Pathol 1997; 50: 275-276.
27. Kyger EM, Krevolin MD, Powell MJ. Detection of the hereditary hemochromatosis gene mutation by real-time fluorescence polymerase chain reaction and peptide nucleic acid clamping. Anal Biochem 1998; 260: 142-148.
28. Totsch M, Schmid KW, Brommelkamp E, et al. Rapid detection of mycobacterial DNA in clinical samples by multiplex PCR. Diagn Mol Pathol 1994; 3: 260-264.
29. Heredia A, Soriano V, Weiss SH, et al. Development of a multiplex PCR assay for the simultaneous detection and discrimination of HIV-1, HIV-2, HTLV-1 and HTLV-II. Clin Diagn Virol 1996; 7: 85-92.
30. Kox LF, Jansen HM, Kuijper S, Kolk AH. Multiplex PCR assay for immediate identification of the infecting species in patients with mycobacterial disease. J Clin Microbiol 1997; 35: 1492-1498.
31. Selo T, Imamura F, Kuriyama K, et al. Effect on prognosis of bone marrow infiltrations detected by magnetic resonance imaging in small cell lung cancer. Eur J Cancer 1997; 33: 2333-2337.
32. Altehoefer C, Blum U, Bathmann J, et al. Comparative diagnostic accuracy of magnetic resonance imaging and immunoscintigraphy for detection of bone marrow involvement in patients with malignant lymphoma. J Clin Oncol 1997; 15: 1754-1760.
33. Devizzi L, Maffioli L, Bonfante V, et al. Comparison of gallium scan, computer tomography, and magnetic resonance in patients with mediastinal Hodgkin's disease. Ann Oncol 1997; 8 (Suppl 1): 53-56.
34. Jacobs TW, Siziopikou KP, Prioleau JE, et al. Do prognostic marker studies on core needle biopsy specimens of breast carcinoma accurately reflect the marker status of the tumour? Mod Pathol 1998; 11: 259-264.
35. Seoudi H, Mortier J, Basile R, Curletti E. Stereotactic core needle biopsy of nonpalpable breast lesions: initial experience with a promising technique. Arch Surg 1998; 133: 366-372.
36. Pui C-H. Childhood leukemias. N Engl J Med 1995; 332: 1618-1630.
37. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89: 2079-2088.
38. de Alava E, Kawai A, Healey JH, et al. EWS FLI1 fusion transcript structure is an independent determinant of prognosis in Ewing's sarcoma. J Clin Oncol 1998; 16: 1248-1255.
39. Huang W, Sun GL, Li XS, et al. Acute promyclocytic leukemia: clinical relevance of two major PML-RAR alpha isoforms and detection of minimal residual disease by retrotranscriptase/polymerase chain reaction to predict relapse. Blood 1993; 82: 1264-1269.
40. Kawai A, Woodruff J, Healy JH, Brennan MF, Antonescu CR, Ladanyi M. SYT SSX gene fusion as a determinant of morphology and prognosis in synovial sarcoma. N Engl J Med 1998; 338: 153-160.
41. American Society of Clinical Oncology. 1997 update of recommendations for the use of tumour markers in breast and colorectal cancer. J Clin Oncol 1998; 16: 793-795.
42. Molino A, Micciolo R, Turazza M, et al. Prognostic significance of estrogen receptors in 405 primary breast cancers: a comparison of immunohistochemical and biochemical methods. Breast Cancer Res Treat 1997; 45: 241-249.
43. Allred DC, Harvey JM, Berardo M, Clark GM. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 1998; 11: 155-168.
44. Raabe NK, Hagen S, Haug E, Fossaa SD. Hormone receptor measurements and survival in 1335 consecutive patients with primary invasive breast carcinoma. Int J Oncol 1998; 12: 1091-1096.
45. Mauri FA, Caffo O, Veronese S, et al. Tissue carcinoembryonic antigen and oestrogen receptor status in breast carcinoma: an immunohistochemical study of clinical outcome in a series of 252 patients with long-term follow-up. Br J Cancer 1998; 77: 1661-1668.
46. Fletcher CDM, Akerman M, Cin PD, et al. Correlation between clinicopathological features and karyotype in lipomatous tumours. A report of 178 cases from the chromosomes and morphology (CHAMP) collaborative study group. Am J Pathol 1996; 148: 623-630.
47. Mertens F, Fletcher CD, Dal Cin P, et al. Cytogenetic analysis of 46 pleomorphic soft tissue sarcomas and correlation with morphologic and clinical features: a report of the CHAMP Study Group. Genes Chromosomes Cancer 1998; 22: 16-25.
48. Kononen J, Bubendorf L, Kalliomemi A, et al. Tissue microarrays for high-throughput molecular profiling of tumour specimens. Nature Med 1998; 4: 844-847.
49. Hacia JG, Brody LC, Chee MS, Fodor SP, Collins FS. Detection of heterozygous mutations in BRCA1 using high density oligonucleotide arrays and two-colour fluorescence analysis. Nature Genet 1996; 14: 441-147.
50. Lieberman R, Crowell JA, Hawk ET, Boone CW, Sigman CC, Kelloff GJ. Development of new cancer chemoprevention agents: role of pharmacokinetic/pharmacodynamic and intermediate endpoint biomarker monitoring. Clin Chem 1998; 44: 420-427.
51. Rosai J. Standardized reporting of surgical pathology diagnoses for the major tumour types. A proposal. The Department of Pathology. Memorial Sloan-Kettering Cancer Center. Am J Clin Pathol 1993; 100: 240-255.
52. Amin MB, Grignon D, Bostwick D, Reuter V, Troncoso P, Ayala AG. Recommendations for the reporting of resected prostate carcinomas. Association of Directors of Anatomic and Surgical Pathology. Ant J Clin Pathol 1996; 105: 667-670.
53. Recommendations for the reporting of breast carcinoma. Association of Directors of Anatomic and Surgical Pathology. Hum Pathol 1996; 27: 220-224.
54. Gamel JW, Meyer JS, Feuer E, Miller BA. The impact of stage and histology on the long-term clinical course of 163.808 patients with breast carcinoma. Cancer 1996; 77: 1459-1464.
55. Tallman MS, Andersen JW, Schiffer CA, et al. All-trans-retinoic acid in acute promyelocytic leukemia. N Engl J Med 1997; 337: 1021-1028.
56. Fenaux P, Wattel E, Archimbaud E, et al. Prolonged follow-up confirms that all-trans retinoic acid followed by chemotherapy reduces the risk of relapse in newly diagnosed acute promyelocytic leukemia. Blood 1994; 84: 666-667.
57. Aaltonen LA, Salovaara R, Kristo P, et al. Incidence of hereditary nonpolyposis colorectal cancer and the feasibility of molecular screening for the disease. N Engl Med 1998; 338: 1481-1487.
58. Pellomaki P, Vasen HF. Mutations predisposing to hereditary nonpolyposis colorectal cancer: database and results of a collaborative study. The International Collaborative Group on Hereditary Nonpolyposis Colorectal Cancer. Gastroenterology 1997; 113: 1146-1158.
59. Fink D. Aebi S, Howell SB. The role of DNA mismatch repair in drug resistance. Clin Cancer Res 1998; 4: 1-6.
60. Gottesman MM, Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 1993; 62: 385-401.
61. Lane D. The promise of molecular oncology. Lancet 1998; 351: 17-20.
62. Jarvinen TA, Holli K, Kuukasjarvi T, Isola JJ. Predictive value of topoisomerase II alpha and other prognostic factors for epirubicin chemotherapy in advanced breast cancer. Br J Cancer 1998; 77: 2267-2273.
63. Anastasi J, Musvee T, Roulston D, Domer PH, Larson RA, Vardiman JW. Pseudo-Gaucher histiocytes identified up to 1 year after transplantation for CML are BCR/ABL-positive. Leukemia 1998; 12: 233-237.
64. Roberts WM, Estrov Z, Ouspenskaia MV, Johnston DA, McClin KL, Zipf TF. Measurement of residual leukemia during remission in childhood acute lymphoblastic leukemia. N Engl J Med 1997; 335: 317-323.
65. Kambouris M, Jackson CE, Feldman GL. Diagnosis of multiple endocrine neoplasia [MEM] 2A, 2B and familial medullary thyroid cancer [FMTC] by multiplex PCR and heteroduplex analyses of RET proto-oncogene mutations. Hum Mutat 1996; 8: 64-70.
66. Perera FP. Environment and cancer: who are susceptible? Science 1997; 278: 1068-1073.
67. Hoivik D, Wilson C, Wang W, et al. Studies on the relationship between estrogen receptor content, glutathione S-transferase pi expression, and induction by 2,3,7,8-tetrachlorodibenzo-p-dioxin and drug resistance in human breast cancer cells. Arch Biochem Biophys 1997; 348: 174-182.